Spinal Muscular Atrophy (SMA): Symptoms, SMN1 Genetic Test and Newborn Screening

The essentials
Spinal muscular atrophy (SMA) is an inherited disease of the nerve cells that move the muscles. It is confirmed by a genetic blood test that counts the copies of two genes, SMN1 and SMN2. Many countries now find it with the newborn heel-prick test, before the first symptoms. Treatment works best when it starts early.
What is spinal muscular atrophy (SMA), at a glance?
SMA damages the motor neurons in the spinal cord, the nerve cells that tell muscles to move. The muscles closest to the trunk, such as the hips and shoulders, weaken most[1].
- Other names: 5q SMA, proximal SMA, Werdnig-Hoffmann disease (type I), Kugelberg-Welander disease (type III)[1].
- How common: about 1 in 10,000 live births. About 1 in 50 people of European or Asian ancestry carries one faulty copy without knowing it[3].
- Key tests: SMN1 and SMN2 genetic test, newborn screening, carrier screening; CK and nerve tests in unclear cases.
SMA is a nerve disease. In muscular dystrophy, by contrast, the muscle fiber itself is faulty.
What are the symptoms of SMA, by type?
The type depends on the age when weakness starts and the best movement reached[1].
| Type | First signs | Best movement reached | Usual SMN2 copies |
|---|---|---|---|
| 0 | Before birth | Very weak at birth, joint stiffness | 1 |
| I | At birth or in the first months | Never sits without help | 1 or 2 |
| II | 6 to 12 months | Sits, but never stands or walks alone | 3 |
| III | After early childhood | Walks, may lose walking later | 3 or 4 |
| IV | Early adulthood | Mild to moderate weakness | 4 or more |
Source of every line: MedlinePlus Genetics[1]. Type I is the most frequent, around 60% of cases[3].
In a baby[2]:
- A floppy baby with little movement and poor head control.
- Feeding or breathing difficulty.
- Small twitches of the tongue (see muscle twitching).
- Missing knee and ankle reflexes on the deep tendon reflex exam.
Later, the signs are difficulty sitting, crawling or walking, tremors and a curved spine (scoliosis)[12].
When should I see a doctor?
When to see a doctor
- Emergency: call 911 if a baby or a person with SMA struggles to breathe, turns blue or gray, or chokes during feeds: breathing difficulty can quickly become an emergency[2].
- Within 24 to 48 hours for a "screen positive" newborn result, or a baby who becomes floppy or feeds poorly: treatment works best before symptoms[5].
- At your next appointment for a child who walks late, falls often or loses skills, or if a relative has SMA and you plan a pregnancy.
What causes SMA, and is it inherited?
SMA is caused by a fault in both copies of the SMN1 gene, on chromosome 5. Without it, the body makes too little SMN protein, and motor neurons die[1][4]. In more than 95% of patients, a part of the gene called exon 7 is missing on both copies[5].
A backup gene, SMN2, makes a little working protein: the more SMN2 copies, the milder SMA tends to be[1], though this is a guide, not a certainty[5].
The inheritance is autosomal recessive, the same pattern as cystic fibrosis[1]:
- Common Both parents are healthy carriers. Each pregnancy then has a 1 in 4 chance of SMA, 1 in 2 of a carrier child, and 1 in 4 of neither.
- Possible A family history of SMA. Carriers are about 1 in 50 in European and Asian populations, 1 in 76 in Hispanic and 1 in 100 in Black populations[3].
- Rare A new fault in one parent's egg or sperm, so only one parent is a carrier[1].
How is SMA diagnosed, and how do I read the genetic test?
The first test is a genetic blood test that counts SMN1 and SMN2 copies[5]. Here is a fictitious report for a floppy 5-month-old baby.
| Test | Result | Reference | Flag |
|---|---|---|---|
| SMN1 exon 7 copy number (MLPA) | 0 copies | 2 copies usual; 1 copy = carrier | A |
| SMN1 exon 8 copy number | 0 copies | 2 copies usual | A |
| SMN2 exon 7 copy number | 2 copies | No normal value: 0 to 4 or more in the population | - |
| Interpretation | Homozygous SMN1 deletion | Consistent with 5q spinal muscular atrophy | - |
- SMN1 = 0: no working copy. With matching symptoms, this confirms SMA[5]. One copy alone means a carrier, not SMA.
- SMN1 = 1 with clear symptoms: the remaining copy is sequenced to look for a small fault[5].
- SMN2 copies: 2 copies usually go with type I, 3 with type II or III, 4 or more with milder forms[1]. The number also guides the treatment plan[5].
Have test results you find hard to follow? BloodSense explains each line in plain words, so you can prepare your questions for the neurologist or genetic counselor.
Explain my lab reportWhat does CK show? Creatine kinase leaks from damaged muscle. In SMA it is often normal or mildly to moderately raised: in 504 patients, about one third with type I or II had a clearly high CK, against over 90% in late-onset type III[9]. Very high values point rather to a muscle disease (see the CPK blood test).
Other tests: an electromyography (EMG) and nerve conduction study, sometimes a muscle biopsy or an MRI, are used when the genetic test is normal and another disease, such as myasthenia gravis, is possible[2].
Which countries screen newborns for SMA?
The lab looks for a missing SMN1 exon 7 by PCR on the heel-prick blood spot, then confirms any positive result with a test that also counts SMN2. It finds about 95% of babies with SMA; carriers are not reported[5].
| Country or region | Status | Source |
|---|---|---|
| United States | All 50 states and Washington, D.C.; federal panel since July 2018 | Cure SMA[6] |
| Germany, Netherlands, Belgium | National program | Varone 2025[5] |
| Italy | 14 regions, about 33% of newborns | Varone 2025[5] |
| Spain | Galicia, Balearic and Canary Islands; pilots in Madrid and Valencia | Varone 2025[5] |
| France | Regional programs (Nouvelle-Aquitaine, Grand Est) | Varone 2025[5] |
| United Kingdom, Romania | Pilot projects | Varone 2025[5] |
| Europe as a whole | 66% of newborns screened (August 2024) | Varone 2025[5] |
Programs change quickly: ask the maternity team. A "screen positive" result is not a diagnosis until the confirmatory test is back.
Can parents be tested before pregnancy?
Yes. US genetics experts recommend offering SMA carrier screening to everyone pregnant or planning a pregnancy, whatever their ancestry[7]. The test counts SMN1 copies (1 copy = carrier), often within a premarital or preconception screening.
Two copies do not remove all risk: some people carry both on the same chromosome and none on the other ("2+0", silent carrier). The test therefore detects 71% to 94% of carriers, depending on ancestry[8]. When both partners are carriers, a test on the pregnancy (chorionic villus sampling or amniocentesis) is possible[12].
Which tests are used to follow SMA?
A neuromuscular team combines motor scores with tests[2]:
- Lung function tests.
- A swallowing study when feeding is difficult.
- Spine X-rays to watch for scoliosis.
- CK and creatinine: in 206 adults on treatment, both tracked disease severity and CK fell by about 18% over 18 months[10]. Low creatinine here reflects small muscle mass.
- Before gene therapy: liver tests, creatinine, a complete blood count with platelets, troponin I and anti-AAV9 antibodies; then liver enzymes for at least 3 months[11].
How is SMA treated?
There is no cure, but three approved medicines raise the amount of SMN protein in different ways[4][12]:
- Nusinersen: injections into the fluid around the spinal cord, repeated over time.
- Risdiplam: a liquid taken by mouth every day.
- Onasemnogene abeparvovec: a gene therapy given once in a vein, for young children.
The choice depends on age, symptoms and SMN2 copies. Screened babies with 1 to 3 copies are treated before symptoms; with 5 or more, follow-up alone is usual[5]. Physical therapy, braces, breathing support, feeding support and spine surgery remain part of care[2].
Can SMA be prevented, and what is life like with it?
SMA itself cannot be prevented, but carrier screening tells couples their risk, and newborn screening allows treatment before nerve cells are lost[5][7].
Before modern treatments, most children with type I did not survive early childhood, many with type II lived into their twenties or thirties, and types III and IV had a normal life expectancy[1]. Treated patients now live longer[4]. Flu and pneumococcal vaccines are usually advised, because a chest infection such as pneumonia is a real risk[12].
Questions to ask your doctor
- How many SMN1 and SMN2 copies does the report show, and what does that mean for my child?
- Which treatment do you suggest, and how soon can it start?
- Which blood and breathing tests will be repeated, and how often?
- Should brothers, sisters or other relatives be tested?
Frequently asked questions
Is SMA the same as ALS?
No. Both affect motor neurons, but SMA is a genetic disease usually seen in childhood, with weakness from loss of the lower motor neurons only[1]. ALS (Lou Gehrig's disease) mostly starts in adults and also affects nerve cells in the brain.
My baby's newborn screen was normal. Can my child still have SMA?
Rarely, yes. About 5% of affected babies carry a small fault that the screening test does not see[5]. If weakness appears, ask for a full genetic test.
Can an adult find out they have SMA?
Yes. Type IV starts in early adulthood with mild weakness of the hips and shoulders[1]. The same SMN1 and SMN2 test confirms it.
Related articles
- Muscular dystrophyThe muscle diseases that SMA is often confused with.
- CPK blood testHow to read a high creatine kinase.
- Premarital screening testsCarrier tests for couples before pregnancy.
- DiseasesAll our guides to diseases and their tests.
References
- MedlinePlus Genetics. Spinal muscular atrophy. US National Library of Medicine. medlineplus.gov (accessed November 17, 2026)
- MedlinePlus. Spinal muscular atrophy. Medical Encyclopedia. US National Library of Medicine. Reviewed October 27, 2025. medlineplus.gov (accessed November 17, 2026)
- Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy: a literature review. Orphanet J Rare Dis. 2017;12(1):124. doi:10.1186/s13023-017-0671-8 (accessed November 17, 2026)
- Mercuri E, Sumner CJ, Muntoni F, et al. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8(1):52. doi:10.1038/s41572-022-00380-8 (accessed November 17, 2026)
- Varone A, Esposito G, Bitetti I. Spinal muscular atrophy in the era of newborn screening: how the classification could change. Front Neurol. 2025;16:1542396. doi:10.3389/fneur.2025.1542396 (accessed November 17, 2026)
- Cure SMA. Newborn screening for SMA. curesma.org (accessed November 17, 2026)
- Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: an ACMG practice resource. Genet Med. 2021;23(10):1793-1806. doi:10.1038/s41436-021-01203-z (accessed November 17, 2026)
- Luo M, Liu L, Peter I, et al. An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. Genet Med. 2014;16(2):149-156. doi:10.1038/gim.2013.84 (accessed November 17, 2026)
- Rudnik-Schöneborn S, Lützenrath S, Borkowska J, et al. Analysis of creatine kinase activity in 504 patients with proximal spinal muscular atrophy types I-III from the point of view of progression and severity. Eur Neurol. 1998;39(3):154-162. doi:10.1159/000007926 (accessed November 17, 2026)
- Freigang M, Wurster CD, Hagenacker T, et al. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol. 2021;8(5):1049-1063. doi:10.1002/acn3.51340 (accessed November 17, 2026)
- US Food and Drug Administration. Zolgensma (onasemnogene abeparvovec-xioi): prescribing information, revised June 2026. fda.gov (accessed November 17, 2026)
- NHS. Spinal muscular atrophy (SMA). Reviewed August 23, 2024. nhs.uk (accessed November 17, 2026)
This page gives general information about spinal muscular atrophy and its tests. It does not replace the advice of the doctor or genetic counselor who knows your or your child's full results.



